Gå direkt till innehåll

Pressmeddelande -

Takeda to Acquire ARIAD Pharmaceuticals, Inc.

Strategic Highlights

  • Highly strategic deal which transforms global oncology portfolio and pipeline by expanding into solid tumors and reinforcing existing strength in hematology
  • Accretive to Takeda’s Underlying Core Earnings by FY2018 and generates immediate and long-term revenue growth
  • Attractive value drivers include two very innovative precision medicines, Iclusig®(ponatinib) and brigatinib, an exciting early stage pipeline and cost synergies
    • Iclusig is a globally commercialized product with continued strong sales growth potential
    • Brigatinib approval in the U.S. is expected in the first half of 2017, with peak sales potential over $1 billion and the potential to be the best-in-class ALK inhibitor
    • Takeda will leverage ARIAD’s research and development capabilities and platform
  • Takeda retains financial flexibility with no impact on dividend policy

Cambridge, Mass. and Osaka, Japan, January 9, 2017 – Takeda Pharmaceutical Company Limited (TSE: 4502) (“Takeda”) and ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) (“ARIAD”) today announced that they have entered into a definitive agreement under which Takeda will acquire all of the outstanding shares in ARIAD for $24.00 per share in cash, or an enterprise value of approximately $5.2 billion. The transaction has been approved unanimously by the boards of directors of both companies, and is expected to close by the end of February 2017, subject to required regulatory approvals and other customary closing conditions. Sarissa Capital, the holder of 6.6% of ARIAD’s common shares, as well as each of the members of ARIAD’s Board of Directors have agreed to tender their shares to Takeda pursuant to the offer.

“The acquisition of ARIAD is a unique opportunity that will enable us to positively impact the lives of more patients worldwide, advance our strategic priorities and generate attractive returns for our shareholders,” said Christophe Weber, president and chief executive officer of Takeda. “This is a very exciting time for Takeda as we will broaden our hematology portfolio and transform our global solid tumor franchise through the addition of two innovative targeted therapies. Opportunities to acquire such high-quality, complementary targeted therapies do not come often, and we are very excited about the potential for this transaction to benefit patients, our shareholders and other stakeholders.”

Paris Panayiotopoulos, president and chief executive officer of ARIAD, said, “We are very pleased to combine with Takeda, which will allow us to not only accelerate our mission to discover, develop and deliver precision therapies to patients with rare cancers, but also deliver immediate and meaningful value to our shareholders through a substantial cash premium. This exciting transaction is a testament to the hard work and dedication of ARIAD’s talented team of employees. We have tremendous respect for Takeda, and I believe our shared commitment to innovation and research-driven cultures will provide for a smooth transition.”

“This transaction is a great outcome for shareholders of ARIAD and Takeda. Both ARIAD and Takeda are passionate about helping cancer patients, and I believe the talent and resources of Takeda coupled with ARIAD’s pipeline and people will accelerate the development of cancer treatments. I would like to extend my deepest gratitude to the management team and everyone at ARIAD for their unrelenting dedication,” said Alexander J. Denner, Ph.D., Chairman of the Board of ARIAD.

Highly strategic deal which transforms global oncology portfolio and pipeline by expanding into solid tumors and reinforcing existing strength in hematology

The acquisition of ARIAD brings two innovative targeted therapies that will expand and enhance Takeda’s existing oncology portfolio. Brigatinib, an investigational drug product, has the potential to add a differentiated, global therapy in a genetically-defined subpopulation of non-small cell lung cancer (NSCLC). The addition of Iclusig will broaden Takeda’s strong hematology franchise to include chronic myeloid leukemia (CML) and a subset of acute lymphoblastic leukemia (ALL). Together, these two innovative targeted therapies will position Takeda for sustainable long-term growth in oncology.

Takeda’s track record of successful oncology product launches [ADCETRIS® (Brentuximab Vedotin), NINLAROTM (ixazomib) and VELCADE® (bortezomib)] means it has the experience and expertise required to deliver the successful launch of brigatinib and to ensure that it achieves global reach and share of voice thereafter.

Accretive to Takeda’s Underlying Core Earnings by FY2018 and generates immediate and long-term revenue growth

The transaction is a compelling opportunity for Takeda shareholders. It will provide immediate revenue, bring considerable long-term revenue potential and deliver synergy savings.

ARIAD provided calendar year 2016 revenue guidance for Iclusig of $170-180 million, and Takeda expects significant long-term revenue potential from the two lead assets.

Takeda projects the acquisition of ARIAD to be accretive to Underlying Core Earnings by FY2018 and broadly neutral in FY2017. Strong revenue growth and synergy savings will offset increased sales and marketing costs for the brigatinib launch.

Attractive value drivers include two very innovative medicines, Iclusig and brigatinib, an exciting early stage pipeline and cost synergies

Iclusig, a commercialized therapy with continued strong sales growth potential, delivers immediate value. Brigatinib, an investigational drug product with peak annual sales potential of over $1 billion, will generate significant long-term value for Takeda. U.S. approval is expected in the first half of 2017 with global filing thereafter. Beyond Iclusig and brigatinib, ARIAD’s commitment and expertise in targeted kinase inhibition linked to strong translational science generated further pipeline opportunities which provide additional long-term upside potential.

Takeda will leverage ARIAD’s R&D capabilities and platform, and largely absorb its R&D costs within Takeda's existing R&D budget. G&A cost synergies will be fully captured by FY2018.

Takeda retains financial flexibility with no impact on dividend policy

The transaction will be funded by up to $4.0 billion of new debt and the remainder from existing cash. FY2017 Net Debt/EBITDA is estimated at approximately 2.6x, which is expected to remain investment grade. The transaction has no impact on Takeda’s dividend policy.

Transaction terms

The acquisition is structured as an all cash tender offer by a subsidiary of Takeda for all of the outstanding shares of ARIAD common stock, followed by a merger in which remaining shares of ARIAD would be converted into the right to receive the same $24.00 cash per share price paid in the tender offer and ARIAD will become an indirect wholly owned subsidiary of Takeda.

The transaction is subject to the tender of a majority of the outstanding shares of ARIAD common stock as well as other customary closing conditions, including expiration of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 and the antitrust laws of applicable foreign jurisdictions. The transaction is expected to close by the end of February 2017.

Takeda Pharmaceuticals U.S.A, a wholly owned subsidiary of Takeda, has established Kiku Merger Co., Inc. to effect the transaction.

Company nameARIAD Pharmaceuticals, Inc.
Headquarters125 Binney Street, Cambridge, Massachusetts 02142, USA
RepresentativeParis Panayiotopoulos, President and Chief Executive Officer
Business descriptionARIAD Pharmaceuticals, Inc., headquartered in Cambridge, Massachusetts is focused on discovering, developing and commercializing precision therapies for patients with rare cancers. ARIAD is working on new medicines to advance the treatment of rare forms of chronic and acute leukemia, lung cancer and other rare cancers. ARIAD utilizes computational and structural approaches to design small-molecule drugs that overcome resistance to existing cancer medicines.
CapitalUS$1,339 million (Additional paid-in capital as of December 31, 2015)
Date of establishmentApril, 1991
Major shareholders and percentage of shares held*Wellington Management Group LLP8.8%
Vanguard Group Inc.6.8%
Relationships between TakedaCapital relationshipNot applicable
Personnel relationshipNot applicable
Transactional relationshipNot applicable
Operating result and financial conditions for the last three years (consolidated)
Accounting periodFiscal year ended December 31, 2013Fiscal year ended December 31, 2014Fiscal year ended December 31, 2015
Net assets
(US$ in thousands)
Total assets
(US$ in thousands)
Net assets per share
(US$ in thousands)
Operating profit
(US$ in thousands)
Net loss
(US$ in thousands)
Net loss per share
* As reported in the 13F filings. Percentage of shares is calculated by dividing the number of shareholdings (as of the end of September 2016) by the number of total shares outstanding of the target company.Change in ownership before and after acquisition
(1)Number of shares already acquired0 shares
Percentage of voting rights: 0%
(2)Number of shares to be acquired194,389,661 shares*
Percentage of voting rights: 100% (planned)
* Total shares outstanding
(1)Board meeting resolutionJanuary 6, 2017
(2)Signing dateJanuary 8, 2017
(3)Commencement date and settlement date of the tender offerFrom January, 2017 to February, 2017
**The initial period of the tender offer will commence within 10 business days following execution of the merger agreement with ARIAD [January 8, 2017 (U.S.)], and will close 20 business days after commencement. If the conditions of the tender offer are not satisfied, the period of the tender offer will be extended, but the extension period will not exceed May 2017 (or August 2017 if antitrust clearance not received).
(4)Completion of acquisitionBy the end of February, 2017 (planned)*

* Fulfillment of the terms and conditions of the U.S. Antitrust Law and the satisfaction of certain other customary conditions are required to complete the acquisition.



At this stage we expect minimal impact on Underlying Revenue and Underlying Core Earnings. We do expect to incur transition and integration expenses, however, these expenses are not material to the current year result. We will incorporate the financial impact in our FY2016 consolidated earnings forecast and announce at the third quarter earnings conference in February 2017.

FY2017 and beyond

It is expected that the acquisition of ARIAD will be accretive to Takeda’s Underlying Core Earnings by FY2018 and broadly neutral in FY2017. Strong revenue growth and synergy savings will offset increased sales and marketing costs for the brigatinib launch. Takeda’s financial guidance, including EPS, for FY2017 will be announced when Takeda reports earnings for FY2016 in May 2017.

Conference Call Webcast Information

Takeda will host a media/investors conference call at 7:30 p.m. EST January 9, 2017 (9:30 a.m. JST January 10, 2017) to discuss the transaction.

You can listen to the conference call at the following link:

A replay of the conference call will be available within 24 hours.

In light of this announcement, ARIAD will not be presenting today at the 35th Annual J.P. Morgan Healthcare Conference.

Relaterade länkar



I Sverige är Takeda ett sälj- och marknadsbolag för både receptbelagda och receptfria läkemedel inom hjärta/kärl, gastroenterologi, inflammatoriska och immunologiska sjukdomar, onkologi, kirurgi och smärta. Takeda har en mycket spännande pipeline med ett antal nya produkter som kommer att lanseras under de kommande åren. Det svenska dotterbolaget har cirka 45 anställda och en omsättning som år 2015 nådde 438 miljoner kronor. Kontoret ligger i Bergshamra, i omedelbar närhet till tunnelbana och bussar.

Takeda globalt är en läkemedelskoncern med inriktning mot specialistvård. Koncernen har cirka 31 300 anställda och en omsättning om cirka 14,6 miljarder Euro. Idag är Takeda representerat i 70 länder och marknadsför och säljer produkter i mer än 100 länder.

Takeda - Japans största läkemedelsföretag har en lång historia, med mer än 230 års erfarenhet inom läkemedelsområdet. Takeda strävar mot en bättre hälsa för människor över hela världen genom ledande innovationer inom läkemedelsområdet.

För mer information vänligen besök: www.takeda.se och/eller www.takeda.com


Henry Werner

Henry Werner

Presskontakt kommunikationsdirektör, Sverige och Norden +46 8 731 28 00

Relaterat innehåll

Med vår passion för sjukvård som drivkraft hoppas vi bidra till en hälsosammare och ljusare framtid för människor världen över

Takeda är ett ledande globalt, forsknings- och innovationsdrivet biofarmaceutiskt företag med huvudkontor i Japan. Vi koncentrerar vår framtida forskning och utveckling kring fyra områden: onkologi, gastroenterologi, centrala nervsystemet och sällsynta diagnoser, samt viss forskning specifikt inriktat mot plasmabaserade terapier och vacciner.

Vi har idag en omfattande forskningsportfölj och vi fokuserar på att utveckla läkemedel som bidrar till att göra skillnad för människor. Våra medarbetare i fler än 80 länder och regioner världen över, arbetar tillsammans med hälso- och sjukvården för att förbättra livskvaliteten för patienter.

För ytterligare information, besök www.takeda.se

Takeda Pharma AB

Box 30143